Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
10 hedge funds and large institutions have $10.2M invested in Soleno Therapeutics in 2016 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
853% more capital invested
Capital invested by funds: $1.07M → $10.2M (+$9.1M)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
25% more funds holding
Funds holding: 8 → 10 (+2)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$693K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$34.9K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.08K |
| 4 |
Citigroup
New York
|
+$98 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$54K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$22.3K |
| 3 |
Morgan Stanley
New York
|
-$12.3K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$10.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VC
1
Vivo Capital
Palo Alto,
California
| $8.88M | +$9.75M | +99,551 | New |
|
|
SM
2
Sabby Management
Miami Beach,
Florida
| $637K | +$693K | +7,074 | New |
|
|
BG
3
Bollard Group
Boston,
Massachusetts
| $480K | – | – | – |
|
|
BIT
4
BlackRock Institutional Trust
San Francisco,
California
| $89K | – | – | – |
|
|
5
Vanguard Group
Malvern,
Pennsylvania
| $63K | +$34.9K | +356 | +102% |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $5K | -$10.8K | -110 | -65% |
|
|
7
UBS Group
Zurich,
Switzerland
| $3K | -$22.3K | -228 | -88% |
|
|
BFA
8
BlackRock Fund Advisors
San Francisco,
California
| $1K | +$1.08K | +11 | New |
|
|
VKH
9
Virtu KCG Holdings
New York
| – | -$54K | -392 | Closed |
|
|
10
Morgan Stanley
New York
| – | -$12.3K | -126 | Closed |
|
|
11
Citigroup
New York
| – | +$98 | +1 | New |
|
SLNO Hedge Fund Activity: Q1 2016 in Review
10 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q1 2016, worth a combined $10.2M — up 853% from $1.07M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new SLNO positions and 2 closed out — a net gain of 2 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $693K. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $54K sold.
- 10 institutional investors held Soleno Therapeutics (SLNO) as of Q1 2016, up from 8 in Q4 2015.
- Funds reported $10.2M of Soleno Therapeutics stock for Q1 2016, up 853% quarter-over-quarter.
- 4 funds opened new Soleno Therapeutics positions in Q1 2016 and 2 closed out, a net change of +2 holders.
- The largest Soleno Therapeutics buyer in Q1 2016 was Sabby Management, an estimated $693K added.
- The largest Soleno Therapeutics seller in Q1 2016 was Virtu KCG Holdings, an estimated $54K sold.
Based on aggregated 13F filings for Q1 2016.